Advertisement

State of the art approach to managing angina and ischemia: tailoring treatment to the evidence

Published:August 18, 2021DOI:https://doi.org/10.1016/j.ejim.2021.08.003

      Highlights

      • No antianginal drug improves survival while they have roughly the same level of evidence on angina relief.
      • A more tailored approach to antianginal treatment may have additional benefits beyond angina relief.
      • Individualizing antianginal drug treatment according the hemodynamic parameters as well as the comorbidities of patients.

      Abstract

      Stable angina represents a chronic and often debilitating condition that affects daily activities and quality of life in patients with chronic coronary syndromes (CCS). Current European Society of Cardiology guidelines recommend a four-step approach for the medical treatment of patients taking into consideration hemodynamic variables (heart rate and blood pressure) and the presence or absence of left ventricular dysfunction. However, CCS patients often have several comorbidities and risk factors. Thus, a tailored approach that takes into consideration patient risk factors and comorbidities may have additional benefits beyond angina relief. This is a state of the art review of stable angina treatment based on the currently available evidence.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Reference

        • Manolis AJ
        • Ambrosio G
        • Collins P
        • Dechend R
        • Lopez-Sendon J
        • Pegoraro V
        • et al.
        Impact of stable angina on health status and quality of life perception of currently treated patients. The BRIDGE 2 survey.
        Eur J Intern Med. 2019; 70: 60-67https://doi.org/10.1016/j.ejim.2019.09.013
        • Virani SS
        • Alonso A
        • Benjamin EJ
        • Bittencourt MS
        • Callaway CW
        • Carson AP
        • et al.
        American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American Heart Association.
        Circulation. 2020; 141: e139-e596
        • Manolis AJ
        • Kallistratos MS
        • LΕ Poulimenos
        • Ambrosio G
        • Dechend R
        • Lopez-Sendon J
        • et al.
        The ESC 2019 CCS guidelines: Have we left our patients and scientific evidence behind?.
        Eur J Intern Med. 2020; 72: 5-8https://doi.org/10.1016/j.ejim.2019.12.012
        • Manolis AJ
        • Poulimenos LE
        • Ambrosio G
        • Kallistratos MS
        • Lopez-Sendon J
        • Dechend R
        • et al.
        Medical treatment of stable angina: A tailored therapeutic approach.
        Int J Cardiol. 2016 Oct 1; 220: 445-453https://doi.org/10.1016/j.ijcard.2016.06.150
        • Zarifis J
        • Grammatikou V
        • Kallistratos M
        • Katsivas A
        Investigators of the Prospective, Noninterventional, Observational Study of the Antianginal Efficacy of Ivabradine During a 4-Month Treatment of a Greek Population With Coronary Artery Disease.
        Clin Cardiol. 2015; 38: 725-732https://doi.org/10.1002/clc.22479
        • Knuuti J
        • Wijns W
        • Saraste A
        • Capodanno D
        • Barbato E
        • Funck-Brentano C
        • et al.
        ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.
        Eur Heart J. 2020; 41: 407-477https://doi.org/10.1093/eurheartj/ehz425
        • Melly L
        • Torregrossa G
        • Lee T
        • Jansens JL
        Puskas JD. Fifty years of coronary artery bypass grafting.
        J Thorac Dis. 2018; 10: 1960-1967
        • Gruentzig A.
        Results from coronary angioplasty and implications for the future.
        American heart journal. 1982; 103 (4 Pt 2): 779-783
      1. Yusuf S, Zucker D, Chalmers TC. Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 1 of 2. The Online journal of current clinical trials. 1994;Doc No 145:[3987 words; 38 paragraphs].

        • Parisi AF
        • Folland ED
        • Hartigan P.
        A Comparison of Angioplasty with Medical Therapy in the Treatment of Single-Vessel Coronary Artery Disease.
        New England Journal of Medicine. 1992; 326: 10-16
      2. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants.
        Lancet. 1997; 350: 461-468
        • Ettehad D
        • Emdin CA
        • Kiran A
        • Anderson SG
        • Callender T
        • Emberson J
        • et al.
        Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.
        Lancet. 2016; 387: 957-967
        • Ridker PM
        • Everett BM
        • Thuren T
        • MacFadyen JG
        • Chang WH
        • Ballantyne C
        • et al.
        Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
        CANTOS Trial Group. 2017 Sep 21; 377 (N Engl J Med): 1119-1131https://doi.org/10.1056/NEJMoa1707914
        • Bangalore S
        • Fakheri R
        • Wandel S
        • Toklu B
        • Wandel J
        • Messerli FH.
        Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials.
        BMJ. 2017; 356: j4
        • Giugliano D
        • Maiorino MI
        • Bellastella G
        • Chiodini P
        • Control Esposito K.Glycemic
        Preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials.
        J Am Heart Assoc. 2019; 8e012356
        • Maron DJ
        • Mancini GBJ
        • Hartigan PM
        • Spertus JA
        • Sedlis SP
        • Kostuk WJ
        • et al.
        Healthy behavior, risk factor control, and survival in the COURAGE Trial.
        J Am Coll Cardiol. 2018; 72: 2297-2305
        • Iqbal J
        • Zhang YJ
        • Holmes DR
        • Morice MC
        • Mack MJ
        • Kappetein AP
        Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up.
        Circulation. 2015; 131: 1269-1277
        • Xie JX
        • Gunzburger EC
        • Kaun L
        • Plomondon ME
        • Barón AE
        • Waldo SW
        • et al.
        Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program.
        Circ Cardiovasc Qual Outcomes. 2019; 12e005455
        • Boden WE
        • O'Rourke RA
        • Teo KK
        • Hartigan PM
        • Maron DJ
        • Kostuk WJ
        • et al.
        Optimal Medical Therapy with or without PCI for Stable Coronary Disease.
        New England Journal of Medicine. 2007; 356: 1503-1516
        • 2D Study Group BARI
        • Frye RL
        • August P
        • Brooks MM
        • Hardison RM
        • Kelsey SF
        • et al.
        A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease.
        New England Journal of Medicine. 2009; 360: 2503-2515
        • De Bruyne B
        • Pijls NH
        • Kalesan B
        • Barbato E
        • Tonino PA
        • Piroth Z
        • et al.
        Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease.
        New England Journal of Medicine. 2012; 367: 991-1001
        • Maron DJ
        • Hochman JS
        • Reynolds HR
        • et al.
        Initial Invasive or Conservative Strategy for Stable Coronary Disease.
        New England Journal of Medicine. 2020; 382: 1395-1407
        • Swedberg K
        • Komajda M
        • Böhm M
        • Borer JS
        • Ford I
        • Dubost-Brama A
        • et al.
        Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
        Lancet. 2010 Sep 11; 376: 875-885https://doi.org/10.1016/S0140-6736(10)61198-1
        • Bangalore S
        • Steg G
        • Deedwania P
        • Crowley K
        • Eagle KA
        • Goto S
        • et al.
        β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.
        JAMA. 2012; 308: 1340-1349
        • Andersson C
        • Shilane D
        • Go AS
        • Chang TI
        • Kazi D
        • Solomon MD
        • et al.
        β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease.
        J Am Coll Cardiol. 2014; 64: 247-252
        • Sorbets E
        • Steg PG
        • Young R
        • Danchin N
        • Greenlaw N
        • Ford I
        • et al.
        β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study.
        Eur Heart J. 2019; 40: 1399-1407
        • Bangalore S
        • Makani H
        • Radford M
        • Thakur K
        • Toklu B
        • Katz SD
        • et al.
        Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials.
        Am J Med. 2014; 127: 939-953
        • Dondo TB
        • Hall M
        • West RM
        • Jernberg T
        • Lindahl B
        • Bueno H
        • et al.
        β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.
        J Am Coll Cardiol. 2017; 69: 2710-2720
        • Harari R
        • Bangalore S.
        Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!.
        Eur Heart J. 2020 Oct 1; 41: 3530-3532https://doi.org/10.1093/eurheartj/ehaa436
        • Fox KM
        • Mulcahy D
        • Findlay I
        • Ford I
        • Dargie HJ.
        Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group.
        Eur Heart J. 1996; 17: 96-103
        • Wallace WA
        • Wellington KL
        • Chess MA
        • Liang CS.
        Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris.
        Am J Cardiol. 1994; 73: 23-28
        • Shu DF
        • Dong BR
        • Lin XF
        • Wu TX
        • Liu GJ.
        Long-term beta blockers for stable angina: systematic review and meta-analysis.
        Eur J Prev Cardiol. 2012; 19: 330-341
        • Kallistratos MS
        • Poulimenos LE
        • Manolis AJ.
        Vasodilator β-blockers: a different class of antihypertensive agents?.
        Future Cardiol. 2014; 10: 669-671
        • Arnold SV
        • Bhatt DL
        • Barsness GW
        • Beatty AL
        • Deedwania PC
        • Inzucchi SE
        • et al.
        Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: A scientific statement from the american heart association.
        Circulation. 2020; 141: e779-e806
        • Murrell W.
        Nitroglycerine as a remedy for angina pectoris.
        Lancet. 1879; 1: 80-81
        • Tardif JC.
        Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases.
        Drugs Today (Barc). 2008; 44: 171-181
        • Tardif JC
        • Ford I
        • Tendera M
        • Bourassa MG
        • Fox K
        • Investigators I.
        Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.
        Eur Heart J. 2005; 26: 2529-2536
        • Tardif JC
        • Ponikowski P
        • Kahan T
        • Investigators AS.
        Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.
        Eur Heart J. 2009; 30: 540-548
        • Fox K
        • Ford I
        • Steg PG
        • Tendera M
        • Ferrari R
        • Investigators B.
        Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2008; 372: 807-816
        • Fox K
        • Ford I
        • Steg PG
        • Tardif JC
        • Tendera M
        • Ferrari R.
        Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure.
        Am Heart J. 2013; 166 (654-661): e656
        • European Medicines Agency.
        Pharmacovigilance Risk Assessment Committee: (PRAC). 2014; (Web site http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Corlentor_and_Procoralan_20/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500181901.pdf Published November 6, 2014. Updated November 6, 2014. Accessed December 10, 2015)
        • Zaza A
        • Belardinelli L
        • Shryock JC.
        Pathophysiology and pharmacology of the cardiac "late sodium current.
        Pharmacol Ther. 2008; 119: 326-339
        • Thomas GR
        • DiFabio JR
        • Gori T
        • Parker JD.
        Once Daily Therapy With Isosorbide-5-Mononitrate Causes Endothelial Dysfunction in Humans. Evidence of a Free-Radical–Mediated Mechanism.
        J Am Coll Cardiol. 2007; 49: 1289-1295
        • Chaitman BR
        • Skettino SL
        • Parker JO
        • Hanley P
        • Meluzin J
        • Kuch J
        • et al.
        Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
        J Am Coll Cardiol. 2004; 43: 1375-1382
        • Chaitman BR
        • Pepine CJ
        • Parker JO
        • Skopal J
        • Chumakova G
        • Kuch J
        Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
        JAMA. 2004; 291: 309-316
        • Stone PH
        • Gratsiansky NA
        • Blokhin A
        • Huang IZ
        • Meng L.
        Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
        J Am Coll Cardiol. 2006; 48: 566-575
        • Savarese G
        • Rosano G
        • D'Amore C
        • Musella F
        • GL Della Ratta
        • Pellegrino AM
        • al; et
        Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis.
        Int J Cardiol. 2013; 169: 262-270
        • Belsey J
        • Savelieva I
        • Mugellu A
        • Camm AJ.
        Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis.
        Eur J Prev Cardiol. 2015; 22: 837-848
        • Villano A
        • Di Franco A
        • Nerla R
        • Sestito A
        • Tarzia P
        • Lamendola P
        • et al.
        Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.
        Am J Cardiol. 2013; 112: 8-13
        • Alexopoulos D
        • Kochiadakis G
        • Afthonidis D
        • Barbetseas J
        • Kelembekoglou P
        • Limberi S
        • et al.
        Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).
        Int J Cardiol. 2016; 205: 111-116
        • Muhlestein JB
        • Grehan S.
        Ranolazine Reduces Patient-Reported Angina Severity and Frequency and Improves Quality of Life in Selected Patients with Chronic Angina.
        Drugs R D. 2013; 13: 207-213
        • Scirica BM
        • Morrow DA
        • Hod H
        • Murphy SA
        • Belardinelli L
        • Hedgepeth CM
        • et al.
        Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
        Circulation. 2007; 116: 1647-1652
        • Morrow DA
        • Scirica BM
        • Karwatowska-Prokopczuk E
        • Murphy SA
        • Budaj A
        • et al.
        Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
        JAMA. 2007; 297: 1775-1783
        • Wilson SR
        • Scirica BM
        • Braunwald E
        • Murphy SA
        • Karwatowska-Prokopczuk E
        • Buros JL
        • et al.
        Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
        J Am Coll Cardiol. 2009; 53: 1510-1516
        • Weisz G
        • Généreux P
        • Iñiguez A
        • Zurakowski A
        • Shechter M
        • Alexander KP
        • et al.
        RIVER-PCI investigators. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
        Lancet. 2016; 387: 136-145
        • Kallistratos MS
        • Poulimenos LE
        • Giannitsi S
        • Tsinivizov P
        • Manolis AJ.
        Trimetazidine in the Prevention of Tissue Ischemic Conditions.
        Angiology. 2019; 70 (Apr): 291-298https://doi.org/10.1177/0003319718780551
        • Tsioufis K
        • Andrikopoulos G
        • Manolis A.
        Trimetazidine and cardioprotection: facts and perspectives.
        Angiology. 2015; 66 (Mar): 204-210https://doi.org/10.1177/0003319714530040
        • Ferrari R
        • Ford I
        • Fox K
        • Challeton JP
        • Correges A
        • Tendera M
        • et al.
        ATPCI investigators. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2020 Sep 19; 396: 830-838https://doi.org/10.1016/S0140-6736(20)31790-6
      3. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.The Lancet 359:1269–1275. doi:10.1016/S0140-6736(02)08265-X.

        • Döring G.
        Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter,double-blind, randomized studies with stable coronary heart disease patients.
        J Cardiovasc Pharmacol. 1992; 20 (Suppl): S74-S81
        • Di Somma S
        • Liguori V
        • Petitto M
        • Carotenuto A
        • Bokor D
        • de Divitiis O
        • et al.
        A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.
        Cardiovasc Drugs Ther. 1993; 7: 119-123
        • Rajaratnam R
        • Brieger DB
        • Hawkins R
        • Freedman SB.
        Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina.
        Am J Cardiol. 1999; 83 (1120–4): A9
        • Fihn SD
        • Gardin JM
        • Abrams J
        • Berra K
        • Blankenship JC
        • Dallas AP
        • et al.
        2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
        J Am Coll Cardiol. 2012; 60: e44-e164
      4. C:/Users/man/Downloads/11 12 15 Sanofi Nicorandil Alert (1).pdf n.d.

      5. (NICE) NIfHaCE. Stable angina: management. https://www.nice.org.uk/guidance/cg126 (4/2016; date last accessed) 2016.

        • Husted SE
        • Ohman EM.
        Pharmacological and emerging therapies in the treatment of chronic angina.
        Lancet. 2015; 386: 691-701
        • Borrás X
        • Garcia-Moll X
        • Gómez-Doblas JJ
        • Zapata A
        • Artigas R
        • researchers As.
        Stable angina in Spain and its impact on quality of life. The AVANCE registry.
        Rev Esp Cardiol (Engl Ed). 2012; 65: 734-741
        • Beltrame JF
        • Weekes AJ
        • Morgan C
        • Tavella R
        • Spertus JA.
        The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study.
        Arch Intern Med. 2009; 169: 1491-1499
        • Ambrosio G
        • Collins P
        • Dechend R
        • Lopez-Sendon J
        • Manolis AJ
        • Camm AJ.
        StaBle Angina: Pe Rcept Ion of Nee Ds, Quality of Life and Mana Gem Ent of Patients (BRIDGE Study)-A Multinational European Physician Survey.
        Angiology. 2018; 3319718796313
        • Williams B
        • Mancia G
        • Spiering W
        • E Agabiti Rosei
        • Azizi M
        • Burnier M
        • 2018 ;.
        • et al.
        Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension.
        J Hypertens. 2018; 36: 2284-2309
        • Ponikowski P
        • Voors AA
        • Anker SD
        • Bueno H
        • Cleland JG
        • Coats AJ
        • et al.
        2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur Heart J. 2016; 37: 2129-2200
        • Zvizdic F
        • Begic E
        • Mujakovic A
        • Hodzic E
        • Prnjavorac B
        • Bedak O
        • et al.
        Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.
        Med Arch. 2019; 73: 72-75
        • Short PM
        • Lipworth SI
        • Elder DH
        • Schembri S
        • Lipworth BJ.
        Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study.
        BMJ. 2011; 342: d2549
        • Members Task Force
        • G Montalescot
        • Sechtem U
        • Achenbach S
        • Andreotti F
        • Arden C
        • et al.
        2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
        Eur. Heart J. 2013; 34: 2949-3003
        • Bakris GL
        • Fonseca V
        • Katholi RE
        • McGill JB
        • Messerli FH
        • Phillips RA
        • et al.
        Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
        JAMA. 2004; 292: 2227-2236
        • Ozyıldız AG
        • Eroglu S
        • Bal U
        • Atar I
        • Okyay K
        • Muderrisoglu H.
        Effects of Carvedilol Compared to Nebivolol on Insulin Resistance and Lipid Profile in Patients With Essential Hypertension.
        J Cardiovasc Pharmacol Ther. 2017; 22: 65-70
        • Padala SK
        • Lavelle MP
        • Sidhu MS
        • Cabral KP
        • Morrone D
        • Boden WE
        • et al.
        Antianginal Therapy for Stable Ischemic Heart Disease: A Contemporary Review.
        J Cardiovasc Pharmacol Ther. 2017; 22: 499-510
        • Kosiborod M
        • Arnold SV
        • Spertus JA
        • McGuire DK
        • Li Y
        • Yue P
        • et al.
        Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
        Journal of the American College of Cardiology. 2013; 61: 2038-2045
        • Gilbert BW
        • Sherard M
        • Little L
        • Branstetter J
        • Meister A
        • Huffman J.
        Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus.
        Am J Cardiol. 2018; 121: 509-512
        • Fragasso G
        • Piatti Md PM
        • Monti L
        • Palloshi A
        • Setola E
        • Puccetti P
        • et al.
        Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
        Am Heart J. 2003; 146: E18
        • Detry JM
        • Sellier P
        • Pennaforte S
        • Cokkinos D
        • Dargie H
        • Mathes P.
        Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.
        Br J Clin Pharmacol. 1994; 37: 279-288
        • Meiszterics Z
        • Kónyi A
        • Hild G
        • Sárszegi Z
        • Gaszner B.
        Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes.
        J Comp Eff Res. 2017; 6: 649-657
        • Pinto D
        • Silva A
        • Heleno B
        • Rodrigues DS
        • Santos I
        • Caetano PA.
        Effect of European Medicines Agency's restrictions on trimetazidine utilization in Portugal.
        Pharmacoepidemiol Drug Saf. 2018; 27: 962-968
        • Bairey Merz CN
        • Handberg EM
        • Shufelt CL
        • Mehta PK
        • Minissian MB
        • Wei J
        • et al.
        A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
        Eur. Heart J. 2016; 37: 1504-1513
        • Shah NR
        • Cheezum MK
        • Veeranna V
        • Horgan SJ
        • Taqueti VR
        • Murthy VL
        • et al.
        Ranolazine in symptomatic diabetic patients without obstructive coronary artery disease: Impact on microvascular and diastolic function.
        J Am Heart Assoc. 2017 May 4; 6e005027https://doi.org/10.1161/JAHA.116.005027
        • Taqueti VR
        • Di Carli MF.
        Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review.
        J Am Coll Cardiol. 2018; 72: 2625-2641
        • Jerling M
        • Abdallah H.
        Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.
        Clin Pharmacol Ther. 2005; 78: 288-297